Home / Business and Economy / GE HealthCare Surges as Analysts Boost Price Targets on Strong Demand
GE HealthCare Surges as Analysts Boost Price Targets on Strong Demand
17 Nov
Summary
- Morgan Stanley raises GE HealthCare's price target to $80
- Q3 revenue rises to $5.1B on strength in imaging and diagnostics
- Orders grow 6% organically, signaling confidence in backlog
As of November 17, 2025, GE HealthCare Technologies Inc. (NASDAQ:GEHC) has emerged as one of the best digital health stocks to buy, according to Wall Street analysts. In the past few weeks, several firms have adjusted their price targets for the company, reflecting their confidence in its growth prospects.
On October 30, 2025, Morgan Stanley raised its price target on GE HealthCare from $74 to $80, while maintaining an Equal Weight rating. The firm's analyst, Patrick Wood, cited solid order trends and backlog strength, stating that their hospital CapEx survey suggested a healthy demand environment. This update came after GE HealthCare reported its third-quarter results on October 29, 2025.
In Q3 2025, GE HealthCare's revenue rose to approximately $5.1 billion, driven by strength in Imaging, Advanced Visualization, and Pharmaceutical Diagnostics, with demand led by the U.S. and EMEA regions. While margins were pressured by tariffs and softer performance in China, the company's orders grew 6% organically, and its guidance inched up, signaling confidence in its backlog and product mix.
GE HealthCare Technologies Inc. is a global medical technology company that provides solutions in imaging, diagnostics, ultrasound, and patient monitoring. The company began trading as a standalone entity in January 2023, following its spin-off from General Electric.
